{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:10:37Z","timestamp":1791202237919,"version":"4.2.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) remains incurable and novel treatments are urgently needed. Preclinical in vitro and in vivo evaluations were performed to assess the potential therapeutic applications of human recombinant tumor necrosis factor (TNF)\u2013related apoptosis-inducing ligand\/Apo2 ligand (TRAIL\/Apo2L) in MM. TRAIL\/Apo2L potently induced apoptosis of MM cells from patients and the majority of MM cell lines, including cells sensitive or resistant to dexamethasone (Dex), doxorubicin (Dox), melphalan, and mitoxantrone. TRAIL\/Apo2L also overcame the survival effect of interleukin 6 on MM cells and did not affect the survival of peripheral blood and bone marrow mononuclear cells and purified B cells from healthy donors. The status of the TRAIL receptors (assessed by immunoblotting and flow cytometry) could not predict TRAIL sensitivity of MM cells. The anti-MM activity of TRAIL\/Apo2L was confirmed in nu\/xid\/bg mice xenografted with human MM cells; TRAIL (500 \u03bcg intraperitoneally daily for 14 days) was well tolerated and significantly suppressed the growth of plasmacytomas. Dox up-regulated the expression of the TRAIL receptor death receptor 5 (DR5) and synergistically enhanced the effect of TRAIL not only against MM cells sensitive to, but also against those resistant to, Dex- or Dox-induced apoptosis. Nuclear factor (NF)-\u03baB inhibitors, such as SN50 (a cell-permeable inhibitor of the nuclear translocation and transcriptional activity of NF-\u03baB) or the proteasome inhibitor PS-341, enhanced the proapoptotic activity of TRAIL\/Apo2L against TRAIL-sensitive MM cells, whereas SN50 reversed the TRAIL resistance of ARH-77 and IM-9 MM cells. Importantly, normal B lymphocytes were not sensitized to TRAIL by either Dox, SN50, or PS-341. These preclinical studies suggest that TRAIL\/Apo2L can overcome conventional drug resistance and provide the basis for clinical trials of TRAIL-based treatment regimens to improve outcome in patients with MM.<\/jats:p>","DOI":"10.1182\/blood.v98.3.795","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"795-804","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":315,"title":["TRAIL\/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications"],"prefix":"10.1182","volume":"98","author":[{"given":"Constantine S.","family":"Mitsiades","sequence":"first","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Shima","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schlossman","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300082514200_B1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med."},{"key":"2020021300082514200_B2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199706053362307","article-title":"Multiple myeloma.","volume":"336","author":"Bataille","year":"1997","journal-title":"N Engl J Med."},{"key":"2020021300082514200_B3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00001622-199903000-00005","article-title":"Bone marrow transplantation in multiple myeloma.","volume":"11","author":"Schlossman","year":"1999","journal-title":"Curr Opin Oncol."},{"key":"2020021300082514200_B4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med."},{"key":"2020021300082514200_B5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1432-1327.1998.2540439.x","article-title":"Apoptosis signaling by death receptors.","volume":"254","author":"Schulze-Osthoff","year":"1998","journal-title":"Eur J Biochem."},{"key":"2020021300082514200_B6","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.4049\/jimmunol.161.6.2833","article-title":"Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.","volume":"161","author":"Griffith","year":"1998","journal-title":"J Immunol."},{"key":"2020021300082514200_B7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand.","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest."},{"key":"2020021300082514200_B8","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.","volume":"271","author":"Pitti","year":"1996","journal-title":"J Biol Chem."},{"key":"2020021300082514200_B9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0014-5793(98)00409-8","article-title":"APO2 ligand: a novel lethal weapon against malignant glioma?","volume":"427","author":"Rieger","year":"1998","journal-title":"FEBS Lett."},{"key":"2020021300082514200_B10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis.","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity."},{"key":"2020021300082514200_B11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.4049\/jimmunol.161.5.2195","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.","volume":"161","author":"Thomas","year":"1998","journal-title":"J Immunol."},{"key":"2020021300082514200_B12","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.4049\/jimmunol.162.9.5616","article-title":"Sensitization of AIDS- Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D.","volume":"162","author":"Mori","year":"1999","journal-title":"J Immunol."},{"key":"2020021300082514200_B13","first-page":"2384","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.","volume":"60","author":"Yu","year":"2000","journal-title":"Cancer Res."},{"key":"2020021300082514200_B14","first-page":"4122","article-title":"Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.","volume":"60","author":"Mitsiades","year":"2000","journal-title":"Cancer Res."},{"key":"2020021300082514200_B15","first-page":"2704","article-title":"Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and express DR4 and DR5 receptors.","volume":"618","author":"Mitsiades","year":"2001","journal-title":"Cancer Res."},{"key":"2020021300082514200_B16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0952-7915(98)80224-0","article-title":"TRAIL: a molecule with multiple receptors and control mechanisms.","volume":"10","author":"Griffith","year":"1998","journal-title":"Curr Opin Immunol."},{"key":"2020021300082514200_B17","first-page":"634a","article-title":"Recombinant human TNF-related apoptosis inducing ligand (hu TRAIL) induces apoptosis of human multiple myeloma (MM) cells.","volume":"92","author":"Treon","year":"1998","journal-title":"Blood."},{"key":"2020021300082514200_B18"},{"key":"2020021300082514200_B19","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0002-9440(10)65708-2","article-title":"Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.","volume":"153","author":"Mitsiades","year":"1998","journal-title":"Am J Pathol."},{"key":"2020021300082514200_B20","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood.V93.4.1287","article-title":"Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.","volume":"93","author":"Treon","year":"1999","journal-title":"Blood."},{"key":"2020021300082514200_B21","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood.V96.9.3147","article-title":"Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.","volume":"96","author":"Treon","year":"2000","journal-title":"Blood."},{"key":"2020021300082514200_B22","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V92.5.1749","article-title":"Anti-estrogens induce apoptosis of multiple myeloma cells.","volume":"92","author":"Treon","year":"1998","journal-title":"Blood."},{"key":"2020021300082514200_B23","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.4049\/jimmunol.157.9.3980","article-title":"A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells.","volume":"157","author":"Zhang","year":"1996","journal-title":"J Immunol."},{"key":"2020021300082514200_B24","first-page":"1059","article-title":"Detection of apoptotic cells from peripheral blood of HIV-infected individuals using a novel monoclonal antibody.","volume":"11","author":"Seth","year":"1997","journal-title":"AIDS."},{"key":"2020021300082514200_B25","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V84.9.3063.3063","article-title":"Interleukin-6 prevents dexamethasone-induced myeloma cell death.","volume":"84","author":"Hardin","year":"1994","journal-title":"Blood."},{"key":"2020021300082514200_B26","doi-asserted-by":"crossref","first-page":"27845","DOI":"10.1074\/jbc.M003428200","article-title":"SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.","volume":"275","author":"Chauhan","year":"2000","journal-title":"J Biol Chem."},{"key":"2020021300082514200_B27","first-page":"66","article-title":"Enzymes and metabolic inhibitors.","volume":"1","author":"Webb","year":"1963","journal-title":"Methods Enzymol."},{"key":"2020021300082514200_B28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.V89.1.227","article-title":"Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.","volume":"89","author":"Chauhan","year":"1997","journal-title":"Blood."},{"key":"2020021300082514200_B29","first-page":"423","article-title":"Growth characteristics of a human myeloma cell line transfected with IL-6 cDNA.","volume":"34","author":"Takahashi","year":"1993","journal-title":"Rinsho Ketsueki."},{"key":"2020021300082514200_B30","first-page":"734","article-title":"Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.","volume":"59","author":"Keane","year":"1999","journal-title":"Cancer Res."},{"key":"2020021300082514200_B31","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1182\/blood.V93.9.3044","article-title":"Role of NF-kappa B in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.","volume":"93","author":"Feinman","year":"1999","journal-title":"Blood."},{"key":"2020021300082514200_B32","doi-asserted-by":"crossref","first-page":"14255","DOI":"10.1074\/jbc.270.24.14255","article-title":"Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence.","volume":"270","author":"Lin","year":"1995","journal-title":"J Biol Chem."},{"key":"2020021300082514200_B33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell."},{"key":"2020021300082514200_B34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1046\/j.1365-2141.1999.01630.x","article-title":"Functional expression of TRAIL by lymphoid and myeloid tumour cells.","volume":"106","author":"Zhao","year":"1999","journal-title":"Br J Haematol."},{"key":"2020021300082514200_B35","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.leu.2401501","article-title":"TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells.","volume":"13","author":"Gazitt","year":"1999","journal-title":"Leukemia."},{"key":"2020021300082514200_B36","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1006\/cyto.1999.0536","article-title":"Apoptosis-induced by TRAIL and TNF-alpha in human multiple myeloma cells is not blocked by BCL-2.","volume":"11","author":"Gazitt","year":"1999","journal-title":"Cytokine."},{"key":"2020021300082514200_B37","first-page":"793","article-title":"Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics [review].","volume":"15","author":"Bonavida","year":"1999","journal-title":"Int J Oncol."},{"key":"2020021300082514200_B38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00062752-199801000-00008","article-title":"Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.","volume":"5","author":"Treon","year":"1998","journal-title":"Curr Opin Hematol."},{"key":"2020021300082514200_B39","first-page":"3513","article-title":"Rare loss-of-function mutation of a death receptor gene in head and neck cancer.","volume":"58","author":"Pai","year":"1998","journal-title":"Cancer Res."},{"key":"2020021300082514200_B40","first-page":"5683","article-title":"Alterations of the DR5\/TRAIL receptor 2 gene in non-small cell lung cancers.","volume":"59","author":"Lee","year":"1999","journal-title":"Cancer Res."},{"key":"2020021300082514200_B41","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4049\/jimmunol.162.5.2597","article-title":"Functional analysis of TRAIL receptors using monoclonal antibodies.","volume":"162","author":"Griffith","year":"1999","journal-title":"J Immunol."},{"key":"2020021300082514200_B42","first-page":"2747","article-title":"Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.","volume":"59","author":"Zhang","year":"1999","journal-title":"Cancer Res."},{"key":"2020021300082514200_B43","first-page":"335","article-title":"Molecular determinants of response to TRAIL in killing of normal and cancer cells.","volume":"6","author":"Kim","year":"2000","journal-title":"Clin Cancer Res."},{"key":"2020021300082514200_B44","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.164.8.3961","article-title":"Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.","volume":"164","author":"Zhang","year":"2000","journal-title":"J Immunol."},{"key":"2020021300082514200_B45","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/blood.V90.10.3984","article-title":"PU.1\/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes.","volume":"90","author":"Himmelmann","year":"1997","journal-title":"Blood."},{"key":"2020021300082514200_B46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/75045","article-title":"Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.","volume":"6","author":"Jo","year":"2000","journal-title":"Nat Med."},{"key":"2020021300082514200_B47","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(00)02659-3","article-title":"Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) [letter].","volume":"356","author":"Nitsch","year":"2000","journal-title":"Lancet."},{"key":"2020021300082514200_B48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ng1097-141","article-title":"KILLER\/DR5 is a DNA damage-inducible p53-regulated receptor gene.","volume":"17","author":"Wu","year":"1997","journal-title":"Nat Genet."},{"key":"2020021300082514200_B49","first-page":"1593","article-title":"p53-dependent and -independent regulation of the death receptor KILLER\/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.","volume":"58","author":"Sheikh","year":"1998","journal-title":"Cancer Res."},{"key":"2020021300082514200_B50","first-page":"847","article-title":"Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.","volume":"60","author":"Nagane","year":"2000","journal-title":"Cancer Res."},{"key":"2020021300082514200_B51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/MCB.20.1.205-212.2000","article-title":"Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL.","volume":"20","author":"Gibson","year":"2000","journal-title":"Mol Cell Biol."},{"key":"2020021300082514200_B52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0955-0674(99)80030-1","article-title":"Multiple signals converging on NF-kappa B.","volume":"11","author":"Mercurio","year":"1999","journal-title":"Curr Opin Cell Biol."},{"key":"2020021300082514200_B53","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1074-7613(00)80400-8","article-title":"Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappa B pathway.","volume":"7","author":"Chaudhary","year":"1997","journal-title":"Immunity."},{"key":"2020021300082514200_B54","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1074-7613(00)80399-4","article-title":"The novel receptor TRAIL-R4 induces NF-kappa B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.","volume":"7","author":"Degli-Esposti","year":"1997","journal-title":"Immunity."},{"key":"2020021300082514200_B55","doi-asserted-by":"crossref","first-page":"33091","DOI":"10.1074\/jbc.273.49.33091","article-title":"TRAIL\/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways.","volume":"273","author":"Muhlenbeck","year":"1998","journal-title":"J Biol Chem."},{"key":"2020021300082514200_B56","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1074-7613(00)80401-X","article-title":"TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappa B.","volume":"7","author":"Schneider","year":"1997","journal-title":"Immunity."},{"key":"2020021300082514200_B57","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1128\/MCB.20.18.6638-6645.2000","article-title":"The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-Terminal kinase.","volume":"20","author":"Lin","year":"2000","journal-title":"Mol Cell Biol."},{"key":"2020021300082514200_B58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000026427","article-title":"Caffeic acid phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and suppresses acute inflammation.","volume":"7","author":"Orban","year":"2000","journal-title":"Neuroimmunomodulation."},{"key":"2020021300082514200_B59","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/7410","article-title":"Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B.","volume":"5","author":"Wang","year":"1999","journal-title":"Nat Med."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/3\/795\/1675757\/h8150100795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/3\/795\/1675757\/h8150100795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T06:44:41Z","timestamp":1704523481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/3\/795\/53252\/TRAILApo2L-ligand-selectively-induces-apoptosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,1]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.3.795","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,8,1]]}}}